Clinical Trial

A Study of MHB048C in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB048C monotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-17.
Trial Details
NCT Number NCT07192120
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
Enrollment 200 participants
Start Date 2026-01-16
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-09